Current therapy for Helicobacter pylori infection in children and adolescents

Canadian Journal of Gastroenterology

Volumn 13, Issue 7, 1999, Pages 571-579

  Gold, Benjamin D ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Children; Eradication; Helicobacter pylori; Infection

Indexed keywords

AMOXICILLIN; AMPICILLIN; BISMUTH SALICYLATE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; NORFLOXACIN; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ADOLESCENT; ANTIBIOTIC THERAPY; CANADA; CHILD; CONFERENCE PAPER; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INFANT; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0032873771     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/634645     Document Type: Conference Paper

References (87)

1. Sonnenberg A. Factors which influence the incidence and the course of peptic ulcer. Scand J Gastroenterol 1988;23:119-40.
2. Macarthur C, Saunders N, Feldman W. Helicobacter pylori, gastroduodenal disease, and recurrent abdominal pain in children. JAMA 1995;273:729-34.
3. Gold BD. Helicobacter pylori infection and peptic ulcer disease. Semin Pediatr Infect Dis 1996;7:265-71.
4. Drumm B, Gormally S, Sherman PM. Gastritis and peptic ulcer disease. In: Walker AW, Durie PR, Hamilton JR, Walker-Smith J, eds. Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management, vol 1. St Louis: BC Decker, 1996:506-18.
5. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer disease: nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.
6. Hirschowitz BI. Zollinger-Ellison syndrome: pathogenesis, diagnosis and management. Am J Gastroenterol 1996;92(Suppl 4):445-85.
7. Ruuska T, Vaajalahti P, Arajarvi P, Maki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 1994;19:181-6.
8. Rao S, Royal LE, Conrad HA, Harris V, Ahuja J. Duodenal ulcer in sickle cell disease. J Pediatr Gastroenterol Nutr 1990;10:117-20.
9. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93:1409-15.
10. Bourke B, Jones N, Sherman P. Helicobacter pylori infection and peptic ulcer disease in children. Pediatr Infect Dis J 1996;15:1-13.
11. Gold BD. Pediatric Helicobacter pylori infection: clinical manifestations, diagnosis and therapy. In: Westblom TU, Czinn SJ, Nedrud JG, eds. Gastroduodenal Disease and Helicobacter pylori: Pathophysiology, Diagnosis and Treatment. Current Topics in Microbiology and Immunology. Berlin: Springer, 1999:71-102.
12. Nagita A, Amemoto K, Yoden A, et al. Diurnal variation in intragastric pH in children with and without peptic ulcers. Pediatr Res 1996;40:528-32.
13. Mertz-Nielsen AJH, Frokiare H, Bukhave K, Rask-Madsen J. Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori positive healthy subjects. Scand J Gastroenterol 1996;31:38-43.
14. Gold BD, Islur P, Policova Z, Czinn S, Neumann AW, Sherman PM. Surface properties of Hetcobacter mustelae and ferret gastrointestinal mucosa. Clin Invest Med 1996;19:92-100.
15. Lichtenberger LM, Romero JJ. Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus layer: implications on the role of ammonium in H pylori induced gastritis. J Gastroenterol Hepatol 1994;9:S13-9.
16. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;i:1272-5.
17. Hill R, Pearman J, Worthy P, Caruso V, Goodwin S, Blincow E. Campylobacter pyloridis and gastritis in children. Lancet 1986;i:387.
18. Cadranel S, Goossens H, De Boeck M, Malengreau A, Rodesch P, Butzler JP. Camplylobacur pyloridis in children. Lancet 1986;i:735-6.
19. Drumm BPS, Cutz E, Karmali M. Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children. N Engl J Med 1987;316:1557-61.
20. Czinn S, Dahms B, Jacobs G, Kaplan B, Rothstein F. Campylobacter-like organisms in association with symptomatic gastritis in children. J Pediatr 1986;109:80-3.
21. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
22. The European Helicobacter pylori Study Group (EHPSG). Current European concepts in the management of H pylori infection: The Maastricht Consensus Report. Gut 1997;41:8-13.
23. Lee J, O'Morain C. Who should be treated for Helicobacter pylori infection? A review of Consensus Conferences and Guidelines. Gastroenterology 1997;113:S99-106.
24. Fennerty MB. What are treatment goals for Helicobacter pylori infection? Gastroenterology 1997;113:S120-6.
25. Hunt R, Thomson ABR. Canadian Helicobacter pylori Consensus Conference. Can J Gastroenterol 1998;12:31-41.
26. Lam SK, Talley NJ. Helicobacter pylori consensus: report of the 1997 Asia-Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
27. Luthra GK, DiNuzzo AR, Gourley WK, et al. Comparison of biopsy and serological methods of diagnosis of Helicobacter pylori infection and the potential role of antibiotics. Am J Gastroenterol 1998;93:1291-6.
28. Cutler AF, Havstad S, Ma CK, et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995;109:136-41.
29. Laine L, Lewin DN, Naritoku W, et al. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1997;45:463-7.
30. Satoh K , Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent . of atrophic gastritis. Am J Gastroenterol 1998;93:569-73.
31. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: A topographic study of H pylori density and distribution. Gastrointest Endosc 1994;40:342-5.
32. Bazzoli F, Zagari M, Fossi S, et al. Urea breath test for the detection of Helicobacter pylori infection. Helicobacter 1997;2:S34-7.
33. Rowland M, Lambert I, Gormally S, et al. Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children. J Pediatr 1997;131:815-20.
34. Kalach N, Briet F, Raymond J, et al. The Carbon urea breath test for the noninvasive detection of Helicobacter pylori in children: Comparison with culture and determination of minimum analysis requirements. J Pediatr Gastroenterol Nutr 1998;26:291-6.
35. 13C-urea breath test value by nationality in Helicobacter pylori-infected children. Scand J Gastroenterol 1998;33:468-72.
36. 13C-urea breath test. J Pediatr Gastroenterol Nutr 1998;27:275-80.
37. Jones NL, Bourke B, Sherman PM. Breath testing for Helicobacter pylori infection in children: A breath of fresh air? J Pediatr 1997;131:791-3.
38. Khanna B, Cutler A, Israel NR, et al. Use caution with serologic testing for Helicobacter pylori infection in children. J Infect Dis 1998;178:460-5.
39. Elitsur Y, Neace C, Triest WE. Comparison between a rapid office-based and ELISA serologic test in screening for H pylori in children. Helicobacter 1997;2:180-4.
40. Czinn SJ. Serodiagnosis of Helicobacter pylori in pediatric patients. J Pediatr Gastroenterol Nutr 1999;28:132-4.
41. Goggin N, Rowland M, Imrie C, Walsh D, Clyne M, Drumm B. Effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease. Arch Dis Child 1998;79:502-5.
42. Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995;41:1-4.
43. Jaspersen D, Koerner T, Schow W, Brennenstuhl M, Raschka C, Hammar C-H. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995;41:5-7.
44. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade astric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767-9.
45. Bayerdorffer E, Newbauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue after cure of Helicobacter pylori infection. Lancet 1995;345:1591-4-
46. Blecker U, McKeithan TW, Hart J, Kirschner BS. Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child. Gastroenterology 1995;109:973-7.
47. Talley NJ. A critique of therapeutic trials in Helecobacter pylori positive functional dyspepsia. Gastroenterology 1994;106:1174-83.
48. Gormally SM, Prakash N, Dumin MT, et al. Association of symptoms with Helicobacter pylori infection inchildren. J Pediatr 1995;126:753-6.
49. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
50. Cutler A, Schubert T. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-9.
51. Thijs J, van Zwet A, Moolenaar W, Wolfhagen M, ten Bokkel H. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized controlled study of efficacy and side effects. Am J Gastroenterol 1996;91:93-7.
52. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
53. Dore MP, Osato MS, Kwon DH, Graham DY, el-Zaatari FA. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis 1998;27:84-9.
54. Skolnick JV. Antibiotic resistance in Helicobacter pylori. Clin Infect Dis 1998;27:90-2.
55. Rozynek E, Dzierzanowska D, Celinska-Cedro D, Jeljaszewicz J. Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland. Eur J Clin Microbial Infect Dis 1997;16:943-4.
56. Glupczynski Y, Labbe M, Burette A, Deltenre M, Avesani V, Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet 1987;i:1096.
57. Blanco M, Pajares JM, Jimenez ML, Lopez-Brea M. Effect of acid inhibition on Campylobacter pylori. Scand J Gastroenterol Suppl 1998;142:107-9.
58. Humphreys H, Bourke S, Dooley C, et al. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut 1988;29:279-83.
59. Dooley CP, McKenna D, Humphreys H, et al. Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy. Am J Gastroenterol 1988;83:278-82.
60. Hui WM, Lam SK, Chau PY, et al. Persistence of Campylobacter pylori despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 1987;32:1255-60.
61. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;ii:1437-42.
62. Solcia E, Villani L, Fiocca R, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol Suppl 1994;201:28-34.
63. Sherman P, Shames B, Loo V, Matlow A, Drumm B, Penner J. Omeprazole therapy for Helicobacter pylori infection. Scand J Gastroenterol 1992;27:1018-22.
64. Vigneri S, Termini R, Scialabba A, Pisciotta G, Di Mario F. Omeprazole therapy modifies the gastric localization of Helicobacter pylori. Am J Gastroenterol 1991;86:1276. (Lett)
65. Peura D. Helicobacter pylori: rational management options. Am J Med 1998;105:424-30.
66. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL. Urea protects Helicobacter (Camplyobacter) pylori from the bacterial effect of acid. Gastroenterology 1990;99:697-707.
67. Fleyou JF, Bahame P, Smith AC, Stockbrugger RE, Rode J, Price AB. Pernicious anemia and Campylobacter-like organisms: is the gastric antrum resistant to colonization? Gut 1989;30:60-4.
68. Rosioru C, Glassman MS, Berezin SH, Bostwick HE, Halata M, Schwarz SM. Treatment of Helicobacter pylori-associated gastroduodenal disease in children. Clinical evaluation of antisecretory vs. antibacterial therapy. Dig Dis Sci 1993;38:123-8.
69. Logan R, Gummett P, Schaufelberger H, et al. Eradication of Helicobacter pylori with clarithromycin and Omeprazole. Gut 1994;35:323-6.
70. Bayerdorffer E, Simon T, Bästlein C, Ottenjann R, Kasper G. Bismuth/ofloxacin combination for duodenal ulcer. Lancet 1987;ii:1467-8. (Lett)
71. Graham DY, Klein PD, Opekun AR, et al. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 1989;84:233-8.
72. Wilhelmsen I, Weberg R, Berstad K, Hausken T, Hundal O, Berstad A. Helicobacter pylori eradication with bismuth subcitrate, oxytetracyclines and metronidazole in patients with peptic ulcer disease. Hepatogastroenterology 1994;41:43-7.
73. Borody TJ, Brandi S, Andrews P, Ferch N, Jankiewicz E, Hyland L. Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:33-8.
74. Graham DY, Lew GM, Ramirez FC, Genta RM, Klein PD, Malaty HM. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection - tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther 1993;7:111-3.
75. Bazzoli F, Zagari RM, Fossi S, et al. Short-term, low dose triple therapy for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7.
76. Moayyedi P, Axon ATR. Efficacy of a new one week triple therapy regime in eradicating Helicobacter pylori. Gut 1994;35(Suppl):S248. (Abst)
77. Labenz J, Stolte M, Rühl GH, Becker T, Tillenburg B, Sollböhmer M, Börsch G. One week low dose triple therapy for cure of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;7:9-11.
78. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I study. Helicobacter 1996;1:138-44.
79. Hopkins RJ, Girardi LJ, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-52.
80. Axon ATR. Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol 1991;6:131-7.
81. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
82. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl 1993;196:34-7.
83. Tucci A, Corinaldesi R, Stanghellini V, et al. One-day therapy for treatment of Helicobacter pylori infection. Dig Dis Sci 1993;38:1670-3.
84. Hopkins RJ. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology 1997;113:S126-30.
85. Dohil R, Israel DM, Hassall E. Effective 2-week therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1996;92:244-7.
86. Casswall TH, Alfven G, Drapinski M, Bergstrom M, Dahlstrom KA. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 1998;28:415-8.
87. van der Wouden EJ, van Zwet AA, Vosmaer GD, Oom JA, de Jong A, Kleibeuker JH. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis 1997;3:385-9.